Log In
Print
BCIQ
Print
Print this Print this
 

Tradjenta, Trajenta, Trazenta, linagliptin

Also known as: BI 1356

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionXanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat diabetic nephropathy in Type II diabetics; Treat Type II diabetes; Treat Type II diabetes as add-on therapy to insulin; Treat Type II diabetes in patients with albuminuria
Regulatory Designation

Partner

Eli Lilly and Co.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today